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DRUG IMPORTATION AND THE HISPANIC PHYSICIAN
RENE F. RODRIGUEZ, M.D.*
ABSTRACT
Personal and commercial importation is a topic that has been
framed in the context of consumers versus industry. Yet it is the phy-
sician and other providers who must be part of the system of care with
a stake in ensuring their patients obtain medicines that promote health.
Both personal and commercial importation has significant risks. In-
vestigations, conducted both in the United States and abroad, deter-
mined personal importation creates risks associated with counterfeit
medications. Commercial importation creates even greater risks on
the level of social disparities. The poor and vulnerable, including
Hispanic patients who are disproportionately represented in this popu-
lation, would be subject to these cheaper and "somewhat-regulated"
drugs, while wealthier, privately insured patients would have access to
fully-regulated domestic supplies. Because the poor cannot afford to
purchase drugs at market prices, they will be left with only one
choice: drugs provided to them from questionable sources. As such,
importation will be paid for by those least able to shoulder the costs:
vulnerable minorities who have no choice but to take the risk of im-
ported drugs.
INTRODUCTION
The current debate over the importation of prescription drugs into
the United States pits consumers against industry, while the advice of
doctors and other health professionals is dismissed. Physicians have a
great stake in the importation debate because they have a responsibil-
ity to oversee the patient's course of treatment with medications that
will be best for him or her.
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Currently, the patient-physician relationship is under attack on
many fronts by third-party payers in the private and public sectors.
Payers naturally want to use all available tools to reduce costs, even
when doing so limits physicians' choices as to a course of treatment.
This paper outlines physicians' general concerns with importation
and warns of the unintended consequences that large-scale importation
will have on the third-party payer health care system. I argue that a
large-scale commercial importation program will create two different
categories of medicines and that the most vulnerable patients, includ-
ing my own, will be put at the greatest risk from the least-regulated
medicines.
PERSPECTIVE OF THE INTERAMERICAN COLLEGE
OF PHYSICIANS AND SURGEONS
The Interamerican College of Physicians and Surgeons (ICPS) was
founded in 1979 to promote cooperation among U.S. Hispanic physicians
and to advance their professional and educational needs. Today, the ICPS
reaches a vast majority of the Hispanic medical community in the United
States and Puerto Rico-over 39,000 physicians-and a growing number
of health professionals in Mexico, the Caribbean, Central and South
America, and Spain through its publications, conferences, and links to
Hispanic medical societies. The ICPS is the largest association of His-
panic physicians in the nation.
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The ICPS has been vocal among patient and physician groups op-
posing prescription drug importation before Congress. Although
many politicians have introduced bills since the late 1990s to de-
regulate personal purchases, 2003 witnessed a much larger importa-
tion initiative, Representative Gil Gutknecht's H.R. 2427.2 This in-
cluded the bulk or "commercial" importation provisions that would al-
low wholesalers abroad to sell to wholesalers in the United States. In
this same year, Florida conducted a report of counterfeit and diverted
drugs in their supply chain because of unscrupulous wholesalers, and
Congress held hearings on how the U.S. drug supply had become a
system overwhelmed with fake, diverted, and adulterated medicine.3
1. Interamerican College of Physicians and Surgeons Home Page, http:/www.
icps.org/main.htm (last visited Aug. 18, 2005).
2. Pharmaceutical Market Access Act of 2003, H.R. 2427, 108th Cong. (2003).
3. OFFICE OF PROGRAM POLICY ANALYSIS & GOV'T ACCOUNTABILITY, JUSTIFICATION
REVIEW: COUNTERFEIT AND DIVERTED DRUGS THREATEN PUBLIC HEALTH AND WASTE STATE
DOLLARS, FLA. STATE LEG. REPORT No. 03-18 (2003), available at http://www. op-
paga. state.fl.us/reports/pdf/031 8rpt.pdf.
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After the passage of the Medicare Modernization Act (MMA),4
importation remained a pressing public issue for several reasons. The
new Medicare prescription drug benefit, approved in late 2003, was
not scheduled for full implementation until 2006. A condition of the
MMA was a provision that the Surgeon General study importation
from Canada and recommend how to implement it for Congress. The
political nature of this issue is accentuated by the fact that several
competing importation bills were debated in Congress before the Sur-
geon General had finished his report. In fact, whereas the Surgeon
General was tasked with studying Canada specifically, the bills in
Congress generally purported to open up the drug supply far wider.
One bill, the Pharmaceutical Market Access Act of 2005, would even
have permitted imports from South Africa.5 (A newer version of this
bill is currently being debated in both houses of Congress and still
contains the South Africa provisions.6)
The problems with these efforts are legion. But most fundamen-
tally, importation undermines the confidence a physician needs to rec-
ommend a course of treatment.
CLINICAL CONCERNS WITH PERSONAL IMPORTATION
Although little is reported in the press, the professional health
community is almost unequivocally opposed to personal importation.
The American Medical Association has testified to that effect, as has
the American Pharmacists Association. The Surgeon General has said
that a legal, regulated method of personal importation would be "ex-
traordinarily difficult. "7
Legislators often refer to personal imports from Canada, but there
is no doubt that American patients are either knowingly or unwittingly
importing from all over the world. Thousands of citizens every year
take bus trips to Mexico, buying medicine of very questionable origin,
under the impression that quality handling and preservation standards
have been met. Many others are snared by Internet Web sites that
boast a Canadian flag, but have no presence of any kind in Canada.
According to a recent FDA report, the counterfeit Canadian Web sites
4. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub.
L. No. 108-173, 117 Stat. 2066 (2003).
5. Pharmaceutical Market Access Act of 2005, H.R. 328/S. 109, 109th Cong. (2005).
6. Pharmaceutical Market Access Act of 2005, H.R. 328, 109th Cong. (2005).
7. DEP'T. OF HEALTH & HUMAN SERVS., REPORT ON PRESCRIPTION DRUG IMPORTATION
(2004), available at http://www.hhs.gov/importtaskforce/Report 1220.pdf.
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vastly outnumber the legitimate ones. 8
Certain state governments are now actively encouraging their citi-
zens to purchase from unregulated channels. The state of Minnesota,
for example, announced that it would permit its citizens to buy drugs
from an unnamed U.K. pharmacy, which has a parallel trade license.
In practice, this means that these "U.K." drugs could have arrived
there from all but five European Union countries. This number in-
cludes many of the new entrants from the former Soviet bloc whose
counterfeiting problems have been acknowledged by international law
enforcement officials.
Even with regard to Canada, which most Americans regard with
high trust, one must exercise a great deal of caution. Although it
would be unfair to disparage Canadian regulations for its own drug
supply, the problem with importation is that imported drugs come
from outside the Canadian drug supply. Canada will not regulate
drugs for export, so the mere incidence that a drug comes from Cana-
dian soil can hardly serve as a guarantor that the material is legitimate
and within a regulated supply chain. As a physician, I cannot assume
that unregulated drugs have the same quality assurance as regulated
drugs. It is that simple.
CLINICAL CONCERNS WITH COMMERCIAL IMPORTATION
Commercial importation is less widely discussed because its bene-
fits accrue to the people between the manufacturer and the patient, in-
stead of to the patient directly. This economic situation creates an in-
centive to move medicine through middlemen from remote countries
with strict price controls. For example, New Zealand has cheaper
drugs than Canada. Thus, Canada may import drugs from New Zea-
land, or from anywhere else, for sale to U.S. patients. In fact, the en-
couraging of commercial importation in the U.K. has spawned an in-
dustry of parallel traders, businesses who move medicine in a
worldwide game of arbitrage.
Needless to say, commercial importation is favored by large pay-
ers rather than individual consumers. Clearly, government purchasers
will have a major interest in managing costs as the population contin-
ues to age and will seek to maximize deep-discounting possibilities
through commercial-size purchases of drugs from countries with price
8. Ricardo Alonso-Zaldivar, FDA Casts Suspicions on Online Pharmacies, SEATTLE
TIMES, June 15, 2005, available at http://seatdetimes.nwsource.com/html/nationworld/
2002336462_fda 15.html.
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controls. Medicaid, the Veterans' Affairs Departments, and other ma-
jor purchasers could be forced, by budgetary pressures, into major im-
port schemes, irrespective of the wishes of the patients in these pro-
grams.
Indeed, and critically, poor patients in government programs often
have little choice or alternative to what is given to them. Patients on
Medicaid can hardly afford a private market insurance plan; and Vet-
erans and military personnel have designated programs for them, in
part to offset the reduced compensation that comes with military ser-
vice. Thus, we have a situation where millions of people will not
"choose" to go to Canada and assume the risk themselves. Instead,
the risk will come to them.
This is why commercial importation of drugs matters to physi-
cians. Although the issue is seemingly about creating savings for in-
termediaries in our third-party payer system of health care, as well as
government payers, the savings for the system comes at the cost of
safety assurance for patients and physicians. I counsel my patients not
to trust a Web site with a Canadian flag and not to hop on a bus to
Mexico for medicine. How could I tell them not to purchase medicine
through their government-sponsored program when often it may be
the only resource available to them? Moreover, if they are suspicious
of this medicine, can I help them opt out? Not without steering them
back to paying rack-room rates and thus negating the purpose of their
insurance coverage, if they have coverage in the first place.
IMPORTATION AND THE HISPANIC PATIENT
A doctor in this situation faces a major quandary about care, but a
doctor treating Hispanic patients has even more reason for concern.
Unfortunately, demographic changes in this country have not made for
an equitable distribution of wealth among classes of the population.
As a consequence, Hispanic patients are far more likely to be enrolled
in government programs. According to U.S. Census figures:
* "Hispanics are much more likely than non-Hispanic
Whites to be unemployed."
* "Hispanics [are] more likely than non-Hispanic Whites to
work in service operations. . . . Hispanics [are] almost
twice as likely to be employed as operators and laborers
than non-Hispanic Whites."
" "Hispanics represent 12.0 percent of the total population
but constitute 23.1 percent of the population living in pov-
erty. In addition, Hispanic children under 18 were much
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more likely than non-Hispanic White children to be living
in poverty (30.3 percent versus 9.4 percent). 9
Hispanic children represented 16.2% of all children in the United
States but constituted 29% of all children in poverty.'0 In this kind of
stratified social situation, a new structure of access to medicines has
the potential to emerge, particularly as costs of health care continue to
rise. This system will consist of two tiers, differing in terms of origin
of medicine and the confidence placed in them.
People in the first-tier, with high income or private coverage, will
be able to afford insurance plans that purchase only those prescription
drugs that have been regulated in a closed system. They will pay for
the confidence that their drugs are legitimate and of high quality. And
they will demand it.
However, people with low or moderate incomes have few choices
in insurance coverage. Government programs, such as Medicaid, are
highly sensitive to cost and subject to constant cost cutting. There-
fore, people with low or moderate incomes will receive medicines that
have been only somewhat-regulated and thus pose an unknown level
of risk. For these people to move into the first-tier, they will have to
purchase their medicines out-of-pocket, which is precisely the prob-
lem that insurance coverage is intended to solve. Additionally, be-
cause they are poor or have limited financial resources, they will have
no choice but to take the second-tier medicines along with the risks.
These are the patients who will receive imported drugs.
SUBSTANTIVE PROBLEMS OF IMPORTED DRUGS
There are many substantive problems with these quasi-regulated
imported drugs. In the United States, the fundamental principle of the
system established by the Prescription Drug Marketing Act is that a
drug has to move from a manufacturer to a patient through regulated
entities. Yet major bills in Congress attempt to "regulate" foreign
middlemen only through the use of contracts." How will there be re-
criminations for non-compliance when there is a serious safety
breach? The FDA does not have the jurisdiction to shut foreign mid-
9. U.S. CENSUS BUREAU, REPORT P20-535, THE HISPANIC POPULATION IN THE U.S. 5-6
(2000), available at www.census.gov/population/socdemo/hispanic/p20-535/p20-535.pdf.
10. Id. at 6.
11. See Pharmaceutical Market Access Act of 2005, S. 109, 109th Cong. (2005); Phar-
maceutical Market Access and Drug Safety Act of 2005, S. 334, 109th Cong. (2005).
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dlemen down, and if the national government abroad wants to save
face, it does not need to shut them down either. Moreover, as we have
seen with Katherine Eban's book Dangerous Doses, criminal counter-
feiters often form shell companies using the names of their relatives. 
12
Simply severing the contract of one does not prevent another business,
run by a criminal's relative, from easily taking over its operations.
A recent AARP study reiterated the findings of many other reports
with regard to mishandling problems of parallel-traded drugs in
Europe. Incorrect leaflets, labeling errors, and problems in translation
have been encountered in that system.13 Sadly, cut-price drugs desig-
nated for poor countries have been diverted for big markups and resale
in Europe after passing through sweltering physical conditions that
could have destroyed their efficacy. The liberal Social Market Foun-
dation has reported that parallel-traded medicine can pass through
twenty or thirty hands before reaching a patient. With each change of
hands, the potential for drug diversion increases greatly.14 I would
never recommend a diverted drug to my patients, but I do not know
how I would prevent them from receiving diverted products under a
commercial importation scheme and save them from the potential
health effects.
CONCLUSION
When considering importation, I urge policymakers to avoid sim-
plistic thinking about senior citizens from Vermont, Minnesota, or
Wisconsin taking buses to nearby brick-and-mortar Canadian pharma-
cies. In recent weeks, none other than a brick-and-mortar Canadian
pharmacy in Hamilton, Ontario was found to be selling a counterfeit
hypertension medication. 5 We all hope that this is the exception to
the rule, but we should not force our citizens to run that risk, irrespec-
tive of their wishes.
Personal importation is very dangerous and completely unadvised
because we have no guarantee of safety or regulation. A physician is
12. KATHERINE EBAN, DANGEROUS DOSES: How COUNTERFEITERS ARE CONTAMINATING
AMERICA'S DRUG SUPPLY (2005).
13. PANos KANAVOS ET AL., PARALLEL TRADING IN MEDICINES: EUROPE'S EXPERIENCE
AND ITS IMPLICATIONS FOR COMMERCIAL DRUG IMPORTATION IN THE UNITED STATES 18
(2005), available at http://assets.aarp.org/rgcenter/health/2005 07_trade.pdf.
14. SOCIAL MARKET FOUND., PARALLEL TRADE IN MEDICINES: RESULTS OF A SOCIAL
MARKET FOUNDATION DISCUSSION SEMINAR 8 (2004).
15. Coroner Probes Five Deaths in Pharmacy Investigation, CBC NEWS, June 23, 2005,
available at http://toronto.cbc.ca/regional/servlet/View?filename=to-pharmacy20050623.
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responsible for a patient's course of treatment and simply cannot, in
good conscience, prescribe an unsafe medication. Commercial impor-
tation, however, is the much larger and much less discussed issue. In
this area, current legislative proposals threaten to undo the closed sys-
tem created by the Prescription Drug Marketing Act, which was cre-
ated precisely to stop drug diversion and quash counterfeiting.
Commercial importation will create a two-tier system for the na-
tion's drug supply. The "haves" will possess options and will find a
way to buy fully-regulated drugs. The "have-nots," the poor, the dis-
enfranchised, and the vulnerable, on the other hand, will have no
choice but to accept somewhat-regulated drugs so their government-
based insurers can save money. The "have-nots" will include a dis-
proportionate number of minorities, especially Hispanics. This puts
the Hispanic physician in an intolerable situation. Ultimately, to rec-
ommend a course of treatment in which he or she has full confidence,
the Hispanic physician would have to ask patients to pay for their
drugs out-of-pocket. Of course, that would save the government
money, but the savings for their system would actually come at the
expense of the patient. Otherwise, the choice is to risk harm each time
a somewhat-regulated drug is used. Ultimately, the personal and the
commercial importation system would result in the minority patient
paying the price in dollars, or in health.
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